 |
|
Preadmission Use of Statins and Outcomes After Hospitalization With PneumoniaPopulation-Based Cohort Study of 29 900 Patients
Reimar W. Thomsen, MD, PhD;
Anders Riis, MSc;
Jette B. Kornum, MD;
Steffen Christensen, MD;
Søren P. Johnsen, MD, PhD;
Henrik T. Sørensen, MD, DMSc
Arch Intern Med. 2008;168(19):2081-2087.
Background While some experimental and clinical research suggests that statins improve outcomes after severe infections, the evidence for pneumonia is conflicting. We examined whether preadmission statin use decreased risk of death, bacteremia, and pulmonary complications after pneumonia.
Methods We conducted a population-based cohort study of 29 900 adults hospitalized with pneumonia for the first time between January 1, 1997, and December 31, 2004 in northern Denmark. Data on statin and other medication use, comorbidities, socioeconomic markers, laboratory findings, bacteremia, pulmonary complications, and death were obtained from medical databases. We used regression analyses to compute adjusted mortality rate ratios within 90 days and relative risks of bacteremia and pulmonary complications after hospitalization in both statin users and nonusers.
Results Of patients with pneumonia, 1371 (4.6%) were current statin users. Mortality among statin users was lower than among nonusers: 10.3% vs 15.7% after 30 days and 16.8% vs 22.4% after 90 days, corresponding to adjusted 30- and 90-day mortality rate ratios of 0.69 (95% confidence interval, 0.58-0.82) and 0.75 (0.65-0.86). Decreased mortality associated with statin use remained robust in various subanalyses and in a supplementary analysis using propensity score matching. In contrast, former use of statins and current use of other prophylactic cardiovascular drugs were not associated with decreased mortality from pneumonia. In statin users, adjusted relative risk for bacteremia was 1.07 (95% confidence interval, 0.69-1.67) and for pulmonary complications was 0.69 (0.42-1.14).
Conclusion The use of statins is associated with decreased mortality after hospitalization with pneumonia.
Author Affiliations: Departments of Clinical Epidemiology (Drs Thomsen, Kornum, Christensen, Johnsen, and Sørensen and Mr Riis) and Clinical Microbiology (Dr Thomsen) and Center of Cardiovascular Research (Dr Johnsen), Aarhus University and Aalborg Hospital, Aalborg, Denmark; and Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts(Dr Sørensen).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Preadmission Use of Statins in Patients With Pneumonia
Madhavi Bollu, Andres Marte-Grau, and Ravi K. Bobba
Arch Intern Med. 2009;169(11):1074.
EXTRACT
| FULL TEXT
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(19):2063.
FULL TEXT
Targeting the Host to Control an Infection Disorder
Kasturi Haldar
Arch Intern Med. 2008;168(19):2067-2068.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Statin use and risk of community acquired pneumonia in older people: population based case-control study
Dublin et al.
BMJ 2009;338:b2137-b2137.
ABSTRACT
| FULL TEXT
Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers
Shyamsundar et al.
Am. J. Respir. Crit. Care Med. 2009;179:1107-1114.
ABSTRACT
| FULL TEXT
Preadmission Use of Statins in Patients With Pneumonia
Bollu et al.
Arch Intern Med 2009;169:1074-1074.
FULL TEXT
History of the cholesterol hypothesis in Britain
Grimes
QJM 2009;102:436-438.
FULL TEXT
Update in Critical Care 2008
Fowler et al.
Am. J. Respir. Crit. Care Med. 2009;179:743-758.
FULL TEXT
Targeting the Host to Control an Infection Disorder
Haldar
Arch Intern Med 2008;168:2067-2068.
FULL TEXT
|
